4.59
0.32 (7.49%)
| Penutupan Terdahulu | 4.27 |
| Buka | 4.52 |
| Jumlah Dagangan | 13,449,030 |
| Purata Dagangan (3B) | 3,784,224 |
| Modal Pasaran | 746,694,976 |
| Harga / Pendapatan (P/E TTM) | 25.50 |
| Harga / Jualan (P/S) | 2.31 |
| Harga / Buku (P/B) | 2.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Keuntungan | -10.18% |
| Margin Operasi (TTM) | -25.64% |
| EPS Cair (TTM) | -0.190 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -45.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -76.20% |
| Nisbah Semasa (MRQ) | 3.34 |
| Aliran Tunai Operasi (OCF TTM) | 78.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 83.30 M |
| Pulangan Atas Aset (ROA TTM) | 12.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Ironwood Pharmaceuticals, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.68% |
| % Dimiliki oleh Institusi | 97.41% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (Citizens, 117.87%) | Beli |
| Median | 7.50 (63.40%) | |
| Rendah | 5.00 (Wells Fargo, 8.93%) | Pegang |
| Purata | 7.50 (63.40%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 4.28 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citizens | 26 Feb 2026 | 10.00 (117.86%) | Beli | 3.96 |
| 05 Jan 2026 | 8.00 (74.29%) | Beli | 4.59 | |
| Wells Fargo | 05 Jan 2026 | 5.00 (8.93%) | Pegang | 4.59 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Jan 2026 | Pengumuman | Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |